Merck & Co., Inc. — Director's Dealing 2021

Nov 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Merck & Co., Inc. (MRK)
CIK: 0000310158
Period of Report: 2021-10-30

Reporting Person: MIZELL STEVEN (EVP, Chief HR Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-30	Common Stock	M	4715	$88.05	Acquired	27896.145	Direct
2021-10-30	Common Stock	F	2323	$88.05	Disposed	25573.145	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-30	Restricted Stock Unit	$	M	4715	Disposed	2021-10-30	Common Stock (4715)	Direct

Footnotes

F1: Holdings include shares acquired in dividend reinvestment transactions.

F2: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

F3: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

F4: The restricted stock units vested and were distributed in equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.